funding Neutral 5

Curis Secures Oncology Runway as Macro Headwinds Pressure Retail Margins

· 3 min read · Verified by 4 sources · By Healthcare Intelligence Brief Editorial
Share

Key Takeaways

  • Curis (CRIS) has successfully pivoted to a clinical-stage oncology focus, securing a cash runway into 2027 through a strategic asset sale and PIPE financing.
  • Meanwhile, broader retail earnings from Torrid and Caleres reveal significant margin pressures from tariffs, signaling a complex macro environment for healthcare supply chains.

Mentioned

Curis company CRIS James E. Dentzer person Torrid company CURV Caleres company CAL Lands' End company LE Oberland company

Key Intelligence

Key Facts

  1. 1Curis (CRIS) reported a net income of $19.4M for Q4 2025, driven by a $27.2M gain from the Erivedge royalty sale.
  2. 2Curis secured a PIPE financing deal providing up to $40.4M in total proceeds, extending its cash runway into 2027.
  3. 3Emavusertib triplet therapy achieved MRD conversion in 5 out of 8 evaluable patients in the AML study.
  4. 4Torrid (CURV) reported a Q4 net loss of $8.1M and closed 151 stores in 2025 as part of a major restructuring.
  5. 5Lands' End (LE) reported that IEPA tariffs reduced gross margins by 200 basis points, highlighting macro-economic headwinds.
  6. 6Caleres (CAL) consolidated sales rose 8.7% to $695.1M, bolstered by the Stuart Weitzman acquisition.
Metric
Q4 Net Income/Loss $19.4M (Gain) ($8.1M) (Loss) ($11.6M) (Op Loss)
Strategic Focus Oncology Pipeline Store Rationalization Brand Portfolio Expansion
Primary Headwind Clinical Trial Costs Tariffs & Promotions Tariffs & SG&A Deleveraging
Cash Runway/Liquidity Into 2027 $84.9M Total Liquidity $610.5M Inventory Value

Analysis

The Q4 2025 earnings cycle has highlighted a stark divergence between clinical-stage biotech resilience and the macro-economic headwinds facing consumer-facing sectors. At the center of the healthcare narrative is Curis (CRIS), which has completed a significant strategic transformation. By selling its Erivedge royalty stream to Oberland for a one-time non-cash gain of $27.2 million, Curis has effectively decoupled its future from legacy assets to focus entirely on its emavusertib oncology pipeline. This move, coupled with a $20.2 million initial PIPE financing, provides the company with a financial runway extending into 2027, a critical buffer as it approaches registrational milestones in the 12-to-18-month window.

Curis’s clinical progress with emavusertib, particularly in the AML triplet study (combining emavusertib, azacitidine, and venetoclax), has shown promising early signals. The company reported that five out of eight evaluable patients achieved MRD (measurable residual disease) conversion. This data is pivotal for Curis as it prioritizes Non-Hodgkin Lymphoma (NHL) and Primary Central Nervous System Lymphoma (PCNSL) for registration. The strategic decision to prioritize NHL over AML reflects a disciplined approach to resource allocation, focusing on the fastest path to market in a high-unmet-need oncology niche. Clinical sites for the CLL (Chronic Lymphocytic Leukemia) study have also been activated across the U.S. and Europe, with proof-of-concept data expected at the ASH Annual Meeting in December 2026.

By selling its Erivedge royalty stream to Oberland for a one-time non-cash gain of $27.2 million, Curis has effectively decoupled its future from legacy assets to focus entirely on its emavusertib oncology pipeline.

While Curis solidifies its clinical footing, the broader market context—as evidenced by the earnings of Torrid (CURV), Caleres (CAL), and Lands' End (LE)—paints a picture of a challenging operational environment. A recurring theme across these retail giants is the impact of IEPA tariffs and markdown allowances on gross margins. Torrid, for instance, saw its Q4 gross margin drop to 30% from 33.6%, driven by promotions and sales deleverage. The company is in the midst of a massive restructuring, having closed 151 stores in 2025 with more planned for 2026. This aggressive cost-cutting, aimed at $40 million in incremental savings, mirrors the broader trend of operational efficiency that biotech firms like Curis are also adopting to preserve capital.

What to Watch

Caleres and Lands' End also reported significant tariff-related headwinds. Lands' End noted that while its underlying gross margin excluding tariffs was a healthy 47%, the unmitigated impact of IEPA tariffs dragged the reported figure down. For the healthcare sector, these retail signals are a proxy for supply chain volatility. As biotech companies navigate global clinical trials and manufacturing, the rising cost of logistics and potential trade barriers remain a secondary but vital risk factor. The ability of Lands' End to grow its U.S. eCommerce customer acquisition by 20% suggests that digital-first strategies remain a bright spot, a trend that health-IT and telehealth providers should monitor as they compete for consumer attention and wallet share.

Looking forward, the healthcare investment landscape will likely remain bifurcated. Companies like Curis that can demonstrate clinical efficacy and secure non-dilutive or milestone-linked funding will find a more receptive market. However, the macro-economic pressures seen in the retail sector—specifically tariff-driven inflation and shifting consumer spending—will continue to weigh on the broader equity markets. Investors should watch for Curis’s ASH data in December and the progress of its PCNSL enrollment as key de-risking events. Simultaneously, the retail sector's ability to mitigate tariff impacts through sourcing shifts will serve as a leading indicator for how healthcare manufacturers might handle similar supply chain shocks in the coming fiscal year.

Timeline

Timeline

  1. Erivedge Wind-down

  2. PIPE Financing

  3. Q4 Earnings Release

  4. Torrid Store Closures

  5. ASH Annual Meeting

Sources

Sources

Based on 4 source articles

Related Stories

funding

IHS Tackles Decades-Old Construction Backlog to Modernize Tribal Healthcare

The Indian Health Service (IHS) is aggressively addressing a multi-billion dollar construction backlog that has left many tribal communities with aging, inadequate medical facilities for decades. This modernization push represents a critical shift in federal healthcare equity, aiming to replace infrastructure that is nearly four times older than private-sector counterparts.

funding

AHF Targets Legislative Support for Expanded HIV and TB Funding in Nigeria

The AIDS Healthcare Foundation (AHF) has launched a strategic advocacy campaign targeting Nigerian lawmakers to secure increased domestic budgetary allocations for HIV/AIDS and Tuberculosis. This initiative seeks to bridge critical funding gaps and reduce the nation's heavy reliance on international donor support as the 2030 deadline for ending the AIDS epidemic approaches.

funding

Manipal Health Files for IPO as Temasek Prepares for Landmark Healthcare Exit

Manipal Health Enterprises has officially filed its Draft Red Herring Prospectus (DRHP) for an initial public offering, marking a pivotal moment for India's second-largest hospital chain. The move follows years of aggressive consolidation and a majority stake acquisition by Singapore’s Temasek.

funding

Temasek-Backed Manipal Health Files for $852M IPO in Landmark India Listing

Manipal Health Enterprises, one of India's largest hospital chains, has officially filed for an initial public offering (IPO) seeking to raise approximately $852 million. The move, backed by majority shareholder Temasek, marks a significant consolidation milestone in the Indian healthcare sector and sets a new benchmark for private equity exits in the region.

How we covered this story

Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled healthcare-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.